FY2024 EPS Estimates for uniQure Reduced by Leerink Partnrs

uniQure (NASDAQ:QURE) – Analysts at Leerink Partnrs reduced their FY2024 EPS estimates for shares of uniQure in a research report issued to clients and investors on Tuesday, December 10th. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnology company will post earnings of ($2.39) per share for the year, down from their previous forecast of ($2.28). The consensus estimate for uniQure’s current full-year earnings is ($3.81) per share. Leerink Partnrs also issued estimates for uniQure’s Q4 2024 earnings at $1.14 EPS, Q1 2025 earnings at ($1.07) EPS, Q2 2025 earnings at ($1.27) EPS, Q3 2025 earnings at ($1.53) EPS, Q4 2025 earnings at $0.21 EPS, FY2025 earnings at ($3.66) EPS and FY2026 earnings at ($1.08) EPS.

A number of other research firms have also issued reports on QURE. Wells Fargo & Company upgraded shares of uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday. Cantor Fitzgerald upped their target price on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday. Leerink Partners upped their target price on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a report on Wednesday. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and upped their target price for the company from $20.00 to $52.00 in a report on Tuesday. Finally, Royal Bank of Canada upped their target price on shares of uniQure from $14.00 to $20.00 and gave the company an “outperform” rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $32.14.

uniQure Price Performance

uniQure stock opened at $15.40 on Friday. uniQure has a 52 week low of $3.73 and a 52 week high of $17.39. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm’s 50-day simple moving average is $6.85 and its 200 day simple moving average is $6.28. The firm has a market capitalization of $750.60 million, a PE ratio of -3.10 and a beta of 0.89.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The business had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million.

Institutional Trading of uniQure

A number of institutional investors and hedge funds have recently bought and sold shares of the business. abrdn plc increased its position in uniQure by 381.7% during the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after purchasing an additional 1,528,581 shares in the last quarter. Franklin Resources Inc. acquired a new stake in uniQure during the 3rd quarter worth approximately $7,360,000. Vanguard Group Inc. increased its position in uniQure by 11.4% during the 1st quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock worth $5,577,000 after purchasing an additional 109,740 shares in the last quarter. Point72 Asset Management L.P. increased its position in uniQure by 336.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock worth $4,816,000 after purchasing an additional 752,889 shares in the last quarter. Finally, Privium Fund Management B.V. increased its position in uniQure by 16.3% during the 3rd quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock worth $3,672,000 after purchasing an additional 104,500 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

Insider Transactions at uniQure

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the transaction, the chief executive officer now directly owns 597,915 shares in the company, valued at $4,562,091.45. This represents a 0.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 4.74% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.